Çѱ¹ÀÀ¿ë¾à¹°ÇÐȸ ½Å¾à°³¹ßÀü¹®°¡ ¾ç¼º ±³À° ÇÁ·Î±×·¥: ½ÉȰúÁ¤
»çȸ: ÃÖ¿µÈñ ±³¼ö (µ¿±¹´ëÇб³)
2023³â 11¿ù 3ÀÏ(±Ý)
Time | Program | |
---|---|---|
10:00~10:10 | Opening Remark | |
Session 1: Recent Issues for New Drug Development & Drug-Drug Interaction | ||
10:10~10:55 | FDAÀÇ ¾à¹° ¾ÈÀü¼º°ú À¯È¿¼º ½É»ç°úÁ¤¿¡¼ RWD/RWEÀÇ È°¿ë (Utilizing Real-World Data and Real-World Evidence in FDA Safety and Efficacy Reviews) ¢º Á¤ÅÂÇö ¹Ú»ç (¹Ì±¹ FDA, CDER) |
|
10:55~11:10 | Q & A | |
11:10~11:55 | ¾àµ¿ÇÐÀû ¾à¹°»óÈ£ÀÛ¿ëÀÇ ÀÌÇØ (Understanding pharmacokinetic drug-drug interaction) ¢º ±è¼ÒÈñ ±³¼ö (¾ÆÁÖ´ëÇб³ ¾àÇдëÇÐ) |
|
11:55~12:10 | Q & A | |
12:10~13:30 | Lunch | |
Session 2: Considerations in the Non-clinical Pharmacokinetic Studies | ||
13:30~14:15 | In vitro ¾à¹°´ë»ç ¿¬±¸ ¹æ¹ý·Ð ¹× µ¥ÀÌÅÍ ÇØ¼® (Methodology and Interpretation of In Vitro Metabolism of a Drug) ¢º ÃÖ¿µÈñ ±³¼ö (µ¿±¹´ëÇб³ ¾àÇдëÇÐ) |
|
14:15~14:30 | Q & A | |
14:30~15:15 | IVIVE¸¦ ÀÌ¿ëÇÑ °£´ë»ç ¿¹Ãø (Estimation of in vitro metabolism and in vivo extrapolation) ¢º ±èÀ¯Ã¶ ±³¼ö (ÀÎÁ¦´ëÇб³ Á¦¾à°øÇаú) |
|
15:15~15:30 | Q & A | |
15:30~15:40 | Intermediate Break | |
Session 3: Practical Strategy for New Drug Development | ||
15:40~16:25 | Èĺ¸¹°ÁúÃÖÀûÈ ¹× ÀÓ»óÁ¦Ãâ¿ë µ¶¼º½ÃÇè (From Lead Optimization to Global IND-enabling Toxicology) ¢º ±è¼öÇå ´ëÇ¥ (Å¥º£½ºÆ®¹ÙÀÌ¿À) |
|
16:25~16:40 | Q & A | |
16:40~17:25 | ºñÀÓ»ó ½Å¾à°³¹ß½Ã °í·Á»çÇ×: IND ¹× ÀÓ»ó½ÃÇè ¼³°è (Considerations for IND and Clinical Trial Design) ¢º ±è°æ¼ø ±³¼ö (ÀÎÁ¦´ëÇб³ Á¦¾à°øÇаú) |
|
17:25~17:40 | Q & A | |
17:40~ | Closing Remark |